Clinical trial
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New…
NCT00386555 · Arog Pharmaceuticals, Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00386555 |
|---|---|
| Title | A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. |
| Official title | Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer. |
| Lead sponsor | Arog Pharmaceuticals, Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | docetaxel, CP-868, 596 + docetaxel, AG-013736 + docetaxel, 596 + AG-013736 + docetaxel |
| Enrollment | 0 |
| Start date | May 1, 2007 |
| First posted | Oct 11, 2006 |
| Last update posted | Aug 9, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: